Medical cannabis is most commonly used by cancer patients for chemotherapy-induced nausea and vomiting, appetite loss, pain, and sleep disruption. Synthetic cannabinoids (dronabinol, nabilone) are already FDA-approved for chemotherapy nausea, and whole-plant programs extend access under state law.
Oncology patients should always coordinate cannabis use with their oncologist — interactions with treatment, immunotherapy considerations, and infection risk from smoked products are real clinical questions.
Most states fast-track or simplify certification for cancer patients, and terminal diagnoses often unlock additional allowances such as caregiver access or waived fees.
The information on this site is for educational purposes only and is not medical or legal advice. Cannabis use carries risks; consult a licensed physician about whether medical cannabis is appropriate for you. Federal status (as of June 2026): marijuana dispensed under state medical licenses and FDA-approved cannabis products are Schedule III controlled substances; all other marijuana remains Schedule I under U.S. federal law.